Regulation of inflammatory pathways by cannabigerol in the collagen induced arthritis model in rats
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22340%2F25%3A43933210" target="_blank" >RIV/60461373:22340/25:43933210 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/25:10505764 RIV/00064165:_____/25:10505764
Result on the web
<a href="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1705962/full" target="_blank" >https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1705962/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fphar.2025.1705962" target="_blank" >10.3389/fphar.2025.1705962</a>
Alternative languages
Result language
angličtina
Original language name
Regulation of inflammatory pathways by cannabigerol in the collagen induced arthritis model in rats
Original language description
Objectives This study aims to assess the anti-inflammatory properties of cannabigerol (CBG) in collagen-induced arthritis (CIA) model in rats, and to determine which inflammatory signaling pathways it affects.Study design Rats were randomized into four groups: placebo (PCB)-p.o. Treated with 1 mL of 0.9% saline once daily, CBG-p.o. Treated with 30 mg of CBG/day, glucocorticoids (GC)-p.o. Treated with methylprednisolone 0.5 mg/kg/day, and negative control (CO)-p.o. Treated with 1 mL of 0.9% saline once daily. CIA was induced in the PCB, GC, and CBG groups. The effect of CBG was assessed by clinical scoring, paw width measurements, ELISA, and analysis of gene (qPCR) and protein (Western blot) expression of selected inflammatory markers in blood and synovial membrane.Results Clinical scores showed significant improvement in the CBG vs. PCB on day 29 and in the GC vs. PCB on days 24, 27, and 29. MMP-3 levels in serum were significantly reduced in the GC vs. PCB. CBG demonstrated a selective anti-inflammatory and immunomodulatory profile, notably through the downregulation of key signaling molecules such as TLRs, systemic NF-kappa B p65, STAT-3, and inflammasome-related components including NLRP1A, NLRP3, AIM2, gasdermin D, and caspase-1. It also reduced IL-1 beta and TNF expression during the early phase of disease and increased expression of the anti-apoptotic gene BCL-2.Conclusion Our findings indicate that CBG modulates distinct components of the inflammatory signaling pathways, and its effects translated into significant improvement in clinical scoring based on swelling, erythema, stiffness in rat CIA model.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30100 - Basic medicine
Result continuities
Project
<a href="/en/project/NU22-08-00346" target="_blank" >NU22-08-00346: Combination of new cannabinoids and advanced formulation methods for treatment of rheumatoid arthritis</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Pharmacology
ISSN
1663-9812
e-ISSN
1663-9812
Volume of the periodical
16
Issue of the periodical within the volume
1705962
Country of publishing house
CH - SWITZERLAND
Number of pages
18
Pages from-to
nestránkováno
UT code for WoS article
001611244500001
EID of the result in the Scopus database
2-s2.0-105021524653